Collegium Pharmaceutical Inc (NASDAQ:COLL) has been given a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and two have given a strong buy recommendation to the company.
Brokers have set a one year consensus price target of $27.00 for the company and are predicting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also given Collegium Pharmaceutical an industry rank of 61 out of 265 based on the ratings given to related companies.
Collegium Pharmaceutical (NASDAQ:COLL) opened at 27.50 on Monday. Collegium Pharmaceutical has a one year low of $11.92 and a one year high of $30.58. The firm’s market capitalization is $568.92 million. The stock has a 50 day moving average price of $22.31 and a 200 day moving average price of $19.47.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, November 12th. The specialty pharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.16. On average, equities analysts predict that Collegium Pharmaceutical will post ($1.87) EPS for the current fiscal year.
COLL has been the subject of several research reports. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, November 30th. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, September 14th.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (NASDAQ:COLL) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication. Xtampza has the same active ingredient as OxyContin OP, which is the abuse-deterrent, extended-release opioid in the United States. The Company has conducted a preclinical and clinical program for Xtampza on abuse-deterrence. These studies and clinical trials demonstrated that chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not change its drug release profile.
For more information about research offerings from Zacks Investment Research, visit Zacks.com